about
Mutational analysis of the LMO4 gene, encoding a BRCA1-interacting protein, in breast carcinomasLung Basal Stem Cells Rapidly Repair DNA Damage Using the Error-Prone Nonhomologous End-Joining PathwayGata-3 is an essential regulator of mammary-gland morphogenesis and luminal-cell differentiation.Gata-3 negatively regulates the tumor-initiating capacity of mammary luminal progenitor cells and targets the putative tumor suppressor caspase-14.Paracrine signaling between tumor subclones of mouse SCLC: a critical role of ETS transcription factor Pea3 in facilitating metastasisKnocking off SOCS genes in the mammary gland.SOX2 Is the Determining Oncogenic Switch in Promoting Lung Squamous Cell Carcinoma from Different Cells of OriginMultiple cells-of-origin of mutant K-Ras-induced mouse lung adenocarcinoma.Cell of origin of lung cancer.Differential hypermethylation of SOCS genes in ovarian and breast carcinomas.The LIM-domain only protein 4 contributes to lung epithelial cell proliferation but is not essential for tumor progression.Impaired lactation in mice expressing dominant-negative FADD in mammary epithelium.Combining Cell Type-Restricted Adenoviral Targeting with Immunostaining and Flow Cytometry to Identify Cells-of-Origin of Lung Cancer.SOCS3 is a critical physiological negative regulator of G-CSF signaling and emergency granulopoiesis.Synergy between the KEAP1/NRF2 and PI3K Pathways Drives Non-Small-Cell Lung Cancer with an Altered Immune Microenvironment.Polycomb Repressive Complex 2 Is a Barrier to KRAS-Driven Inflammation and Epithelial-Mesenchymal Transition in Non-Small-Cell Lung Cancer.Cell of origin of small cell lung cancer: inactivation of Trp53 and Rb1 in distinct cell types of adult mouse lung.FGFR3-TACC3 is an oncogenic fusion protein in respiratory epitheliumDistinct initiating events underpin the immune and metabolic heterogeneity of KRAS-mutant lung adenocarcinoma"Keaping" a lid on lung cancer: the Keap1-Nrf2 pathwayCharacterization of a novel human BFL-1-specific monoclonal antibodyTargeting platelets for improved outcome in KRAS-driven lung adenocarcinoma
P50
Q28202446-BAD88602-0155-4208-8DDF-D3967F767507Q28818153-B5D1A392-30A5-4225-A818-8C1E695F6902Q34573593-D16C6E83-D602-425A-890A-D5FE420BE062Q35531064-392A4A62-EEBD-4E30-A8DA-15CEA0ABDF81Q35952716-16BF81D4-AF0A-49B8-90C4-B9561190E0BEQ36766400-075189F8-4288-4DB4-8908-C8AAC4E2C08DQ37340964-17BE8518-4C07-41AE-9694-6BD9B3D0C227Q37687546-4D5DC6DC-D6F9-4AA1-895E-0A8CF7994803Q37769327-DF1EE05A-4780-4011-91F8-90239A82AF3EQ38336792-0738ADC2-9A23-449E-912F-4FE6B12EEE78Q41690163-9D571246-F299-4694-91B0-375445349765Q43718801-ECB7F903-0193-40BC-A97F-72CDD5322F56Q47555604-5B6F8378-83AF-47FE-9D71-5C6D87D365BBQ51027830-71777BDF-4E2D-4F81-937D-A8308BAA17BBQ52727327-ACDB2205-19BF-4659-BA28-C54033B369CEQ52889035-64CCB0CF-0929-4759-8036-F6BDB5BB85D3Q53241385-44E55598-323C-4E63-8216-B8CA6E3F5774Q59357287-51CD969A-724F-4995-93CF-C1D51140F5C3Q90100630-8247C791-BD84-4837-A080-73F6505D4790Q90228199-E01AA6AA-CA48-4E9F-8D62-826B3DEAC98AQ91260479-C7780952-7AFC-4F50-99C0-72D88C10B222Q96340455-18C3AB61-E7D0-44ED-8352-B60E51E8A884
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Kate D Sutherland
@ast
Kate D Sutherland
@en
Kate D Sutherland
@es
Kate D Sutherland
@nl
type
label
Kate D Sutherland
@ast
Kate D Sutherland
@en
Kate D Sutherland
@es
Kate D Sutherland
@nl
prefLabel
Kate D Sutherland
@ast
Kate D Sutherland
@en
Kate D Sutherland
@es
Kate D Sutherland
@nl
P106
P21
P31
P496
0000-0002-7453-3366